S. Wittebol
- Hematology top 2%
- Acute Myeloid Leukemia Research 5
- Multiple Myeloma Research and Treatments 3
- Genetics top 10%
- Chronic Lymphocytic Leukemia Research 4
- Oncology top 10%
- Drug Transport and Resistance Mechanisms 2
- Physiology top 10%
-
- Childhood Cancer Survivors' Quality of Life 3
-
- Cancer therapeutics and mechanisms 3
-
- Lymphoma Diagnosis and Treatment 3
-
- Acute Lymphoblastic Leukemia research 2
- Co-authors
- Pieter SonneveldBob LöwenbergJoost M. BakkerHM LokhorstTuna MutisMichael S. van der VeerMichel de WeersBerris van Kessel
- Cited by
- HematologyGeneticsOncology
- Partner nations
- NetherlandsBelgiumUnited States
In The Last Decade
S. Wittebol
16 papers receiving 571 citations
Peers
Comparison fields: 5 of 50
- Hematology 387
- Genetics 114
- Oncology 272
- Physiology 29
- Pediatrics, Perinatology and Child Health 80
Countries citing papers authored by S. Wittebol
This map shows the geographic impact of S. Wittebol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Wittebol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Wittebol more than expected).
Fields of papers citing papers by S. Wittebol
This network shows the impact of papers produced by S. Wittebol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Wittebol. The network helps show where S. Wittebol may publish in the future.
Co-authorship network
The 25 scholars most cited alongside S. Wittebol, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 36 | |
| 2 | 2013 | 8 | |
| 3 | Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011. | 2011 | 4 |
| 4 | 2011 | 55 | |
| 5 | 2010 | 168 | |
| 6 | 2009 | 19 | |
| 7 | 2009 | 5 | |
| 8 | [Acquired von Willebrand syndrome]. | 2003 | 2 |
| 9 | [Immunologic phenomena as the first sign of myelodysplastic syndrome]. | 2001 | 2 |
| 10 | 1999 | 76 | |
| 11 | 1998 | 13 | |
| 12 | 1996 | 19 | |
| 13 | Residual normal, highly proliferative progenitors can be isolated from the CD34+/33- fraction of AML with a more differentiated phenotype (CD33+). | 1995 | 19 |
| 14 | Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia. | 1994 | 18 |
| 15 | 1993 | 6 | |
| 16 | 1993 | 131 |
About S. Wittebol
S. Wittebol is a scholar working on Hematology, Genetics, Gastroenterology, Pathology and Forensic Medicine and Immunology and Allergy, having authored 16 papers that have together received 581 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (5 papers), Chronic Lymphocytic Leukemia Research (4 papers), Cancer therapeutics and mechanisms (3 papers), Childhood Cancer Survivors' Quality of Life (3 papers), Multiple Myeloma Research and Treatments (3 papers), Lymphoma Diagnosis and Treatment (3 papers), Acute Lymphoblastic Leukemia research (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). The work is most often cited by research in Hematology (387 citations), Genetics (114 citations), Oncology (272 citations), Physiology (29 citations) and Pediatrics, Perinatology and Child Health (80 citations). S. Wittebol has collaborated with scholars based in Netherlands, Belgium and United States. Frequent co-authors include Pieter Sonneveld, Bob Löwenberg, Joost M. Bakker, HM Lokhorst, Tuna Mutis, Michael S. van der Veer, Michel de Weers, Berris van Kessel, Paul W.H.I. Parren and M. Schoester. Their work appears in journals such as Blood, Leukemia, Haematologica, Clinical Infectious Diseases and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.